Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway
about
A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell linesKinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors.Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.Dynamins and BAR Proteins-Safeguards against Cancer.Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics.Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed.Small molecule screening in zebrafish: an in vivo approach to identifying new chemical tools and drug leads.Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivoCombined zebrafish-yeast chemical-genetic screens reveal gene-copper-nutrition interactions that modulate melanocyte pigmentation.Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafishRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?Systematic differences in signal emitting and receiving revealed by PageRank analysis of a human protein interactome.p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.Endocrine side effects of broad-acting kinase inhibitors.Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells.Fate and plasticity of the epidermis in response to congenital activation of BRAF.A filter-based feature selection approach for identifying potential biomarkers for lung cancer.PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signalingDown-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1.Impact of the mitogen-activated protein kinase pathway on the subproteome of detergent-resistant microdomains of colon carcinoma cells.Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp miceSynergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors.Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancerPhase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.CCM3/SERPINI1 bidirectional promoter variants in patients with cerebral cavernous malformations: a molecular and functional studyAcute mitochondrial inhibition by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) 1/2 inhibitors regulates proliferation.Expanding the concepts and tools of metabolic engineering to elucidate cancer metabolism.MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways.Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradationChrysophanic Acid Induces Necrosis but not Necroptosis in Human Renal Cell Carcinoma Caki-2 Cells.Therapeutic targeting of MLL.Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.Protein kinase inhibitors: contributions from structure to clinical compounds.The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells.Emerging Raf inhibitors.
P2860
Q28540936-E8686FD2-DB0E-4CDD-85D5-0FC65CECCD3BQ33431755-B1AD357D-B31C-4D73-9916-FB0E8F7EDF4DQ33496309-E484E46C-6EF2-4861-9DBE-1756CC969D69Q33691759-2960B94B-2AC6-4E71-98F2-E0DD0FD1227BQ33699026-C0D16023-83BE-4564-B642-3A0FC1251133Q33756524-A85B9C65-6BDB-4A7B-B488-7C43630A5935Q33780816-238A6DEE-38A2-4EAF-BF6C-B370DD719A19Q34029188-CBB38E4B-5B74-4115-8ECC-E94F0C1C4B5CQ34094097-9DA63B68-3CEC-412C-8F81-255EC13FBEDAQ34109756-8D6E7F9A-11CF-4059-BC31-587D4660200DQ34123441-E1353315-0C17-4321-80E9-E6413220B7E9Q34149419-7287DDEB-5DDF-4107-8DEB-238824F52CF8Q34307356-A9FDC789-11CD-40BE-A930-DD13962A443DQ34412979-379F4569-12CF-43B1-996E-7F4D9E852466Q34427564-4D221326-F6DA-4E68-90E3-CEB2C3EC8676Q34472383-2F7B761A-0322-4569-8E64-9243261D35F4Q34574985-0BA9D97A-2E3C-418C-B493-846E5AFDC3D2Q34881610-DFE84A95-02DC-4345-9B3F-F68128BC03C9Q34899259-72310945-08CB-44FA-BF1B-FA28D39403C1Q35189076-9F49FA74-DD21-4CA8-940B-90DE156924E9Q35227481-D193A237-F815-4CF9-9D91-33DCA193DF69Q35227751-A1C6D985-C3D7-4049-837B-516FC082CC11Q35379875-B0A35537-D966-496E-944D-76D23273DC95Q35538411-89AFB72A-E0E3-4044-808D-836980C1B03BQ35558993-3AC4FBFA-FA33-464D-A3C9-C9BC7420270DQ35679353-7E93CEB9-CDAA-4685-9458-43F82AEBB97FQ35749960-DB78ABD2-B06C-4C9A-BA11-9BD04B3740FAQ35951620-EA13C962-FB00-4F8A-A09E-AD07439A2CAFQ36086845-6D43AAA1-8D8C-472D-8467-584C97273BCBQ36163127-5BD49FD0-9D4E-4A8C-B230-9DDA162BA274Q36579425-0DE88716-B6ED-46C5-BDFE-6FD950EBA14EQ36650394-8CB46057-BFEE-46A0-AF3C-BD36C9B1701AQ36781119-F8BAB54E-3D64-44C1-A8D1-192B69BE5024Q36832181-1795FB71-955B-4BE9-A117-4B0300996B84Q37066413-5E461061-F2EF-4012-B962-6DD4D69EFEC9Q37234595-8077E9A4-01D4-45F0-B86C-EA67955678B4Q37343475-EB4BBED8-38BF-4D93-83E7-3C1D7592F0F1Q37417742-4C1FF27B-8AD4-4F48-BE62-F9A1EADBE065Q37440267-1930B1AF-4985-4B67-8488-121F43DC94CFQ37588717-A627980D-1C29-44EA-BC67-00A6CDA02DCE
P2860
Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Advances in the development of ...... tivated protein kinase pathway
@ast
Advances in the development of ...... tivated protein kinase pathway
@en
Advances in the development of ...... tivated protein kinase pathway
@nl
type
label
Advances in the development of ...... tivated protein kinase pathway
@ast
Advances in the development of ...... tivated protein kinase pathway
@en
Advances in the development of ...... tivated protein kinase pathway
@nl
prefLabel
Advances in the development of ...... tivated protein kinase pathway
@ast
Advances in the development of ...... tivated protein kinase pathway
@en
Advances in the development of ...... tivated protein kinase pathway
@nl
P3181
P1476
Advances in the development of ...... tivated protein kinase pathway
@en
P2093
Judith S Sebolt-Leopold
P304
P3181
P356
10.1158/1078-0432.CCR-08-0333
P407
P577
2008-06-15T00:00:00Z